Meantime, Viswanathan's work highlighted that lipid peroxidase pathway inhibition is prevalent in therapy‐resistant cancers, suggesting GPX4 and lipid peroxidation as therapeutic targets to combat drug resistance [133]. This evidence concerns the gene GPX4 and cancer.